1. Taiwan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
WeLeader Biomedical Co. Ltd.

WeLeader Biomedical Co. Ltd.

TTPEX:7713
72.10
TWD
-0.40
(-0.55%)
5.15EPS
12.98P/E
3.24BMarket Cap
Nov 18Next Earn
WeLeader Biomedical Co. Ltd.
TPEX:7713
(Taipei Exchange)

Recent

price

72.10

P/E

ratio

12.98

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
TWD
16.22
30.17
29.63
23.08
23.84
24.68
26.61
Revenue per Share
1.18
3.79
4.4
3.74
4.09
4.64
5.49
Basic EPS, GAAP
3.24
7.68
-10.91
2.85
2.51
2.21
3.93
Free Cash Flow per Basic Share
0.79
0.8
0.28
0.73
2.3
3.41
- -
Dividend per Share
6.5
8.6
15.54
20.34
21.85
27.71
26.4
Book Value per Share
6.34
8.45
15.41
20.25
21.75
27.65
26.27
Tangible Book Value per Share
42
28
35
41
42
45
45
Basic Weighted Avg Shares
675
841
1,036
941
991
1,109
1,209
Sales/Revenue/Turnover
10.08
15.77
18.74
20.99
21.61
23.54
25.63
Operating Margin (%)
109
114
110
104
109
124
130
Depreciation Expense
49
106
154
152
170
209
249
Net Income, GAAP
19.91
19.54
20.12
21.32
20.91
20.09
19.64
Effective Tax Rate (%)
7.28
12.57
14.85
16.19
17.17
18.8
20.61
Profit Margin (%)
52
105
16
49
122
348
248
Working Capital
257
162
515
477
618
757
869
LT Debt
270
357
646
846
908
1,260
1,200
Total Equity
- -
15.32
15.18
10.83
10.5
10.74
12.3
Return on Invested Capital (%)
- -
16.36
15.79
11.12
11
11.23
13.05
Return on Capital (%)
- -
33.7
30.65
20.41
19.41
19.23
21.8
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
107
92
110
LT Borrowings
488
491
478
LT Finance Leases
268
267
391
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
45
45
Market Capitalization
3,338
3,065
3,238

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
780
807
697
Cash, Cash Equivalents & STI
335
357
197
Accounts Receivable, Net
304
295
343
Inventories
118
133
130
Total Current Liabilities
432
591
449
Payables & Accruals
- -
- -
- -
ST Debt
107
92
110
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
38%
38.71%
Free Cash Flow
- -
-72.87%
-4.73%
Net Income, GAAP
- -
38.85%
22.53%
Sales/Revenue/Turnover
- -
11.19%
11.92%
Total Cash Common Dividend
- -
79.61%
60.17%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
235
253
256
248
991
2025
245
273
296
295
1,109
2026
279
339
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.06
1
1.06
0.97
4.09
2025
0.9
1.1
1.32
1.27
4.64
2026
1.17
1.73
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.3
2025
- -
- -
- -
- -
3.41
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
WeLeader Biomedical Co., Ltd. WeLeader Biomedical Co., Ltd. (7713.TWO) operates as an agent, wholesaler, and distributor of in vitro diagnostic products and medical devices in Taiwan. The company provides a comprehensive range of medical testing systems and equipment, including serum biochemistry integration platforms, clinical care systems, and medical information integration systems; blood gas electrolyte analyzers; urine analyzers; integrated fully automatic biochemical analyzers; fully automatic electronic luminescence immunoassay products; fully automatic modular biochemical immune assay products; TTA automated pre-processing products; POCT central laboratory products; and CCM fully automated track processing products. It serves research institutions, schools, hospitals, and laboratories primarily in Taiwan, with headquarters located at No. 80, Minzu 1st Road, 19th Floor, Kaohsiung, Taiwan, where the company was founded in 1992. In January 2024, WeLeader Biomedical listed its common stock on the Taipei Exchange (TPEX), marking its initial public offering and enhancing its access to capital markets for potential business expansion.